Skip to main content
. 2019 Aug 21;2019:5354320. doi: 10.1155/2019/5354320

Table 1.

Factors influencing IBD quality of life.

Univariate analysis Multivariate model: backward elimination
Variables N
435
Unadjusted OR
Risk of having pathological IBDQ (≤170)
Adjusted OR
Risk of having pathological IBDQ (≤170)
Adjusted OR
Risk of having pathological IBDQ (≤170)
Disease
 CD 203 1 1 1
 UC 232 0.59 (0.40-0.88) 0.44 (0.28-0.71) 0.44 (0.28-0.70)
Age group
 <45 189 1
 ≥45 246 1.19 (0.80-1.76)
Sex
 Men 231 1
 Women 204 1.20 (0.81-1.76)
Disease latency
 ≤1 year 335 1
 >1 year 100 1.03 (0.96-1.11)
Disease duration
 ≤5 years 80 1
 >5 years 355 0.99 (0.97-1.01)
Current smoking status
 Nonsmoker 371 1
 Smoker 64 0.17 (0.68-2.01)
Current alcohol intake
 No 189 1 1
 Yes 246 0.63 (0.42-0.92) 0.69 (0.44-1.07)
Disease active (pMayo > 1 or HBI > 4)
 Inactive 332 1 1 1
 Active 103 5.62 (3.47-9.12) 5.47 (3.11-9.61) 5.67 (3.30-9.76)
High faecal calprotectin (>250)
 No 248 1 1
 Yes 187 1.90 (1.28-2.82) 1.18 (0.74-1.87)
Anaemia (Hb < 12 females, <13 males)
 No 373 1 1 1
 Yes 62 2.69 (1.68-5.80) 2.05 (1.09-3.86) 2.15 (1.15-4.03)
UC localization
 E1/E2 123 1
 E3 109 1.34 (0.77-2.33)
CD behavior
 Nonstricturing, nonpenetrating 104 1
 Stricturing 65 1.01 (0.54-1.89)
 Penetrating 34 1.26 (0.58-2.73)
Localization
L1 terminal ileum 48 1
L2 colon or L3 ileocolon 148 1.19 (0.61-2/29)
L4 upper or upper+other 7 1.86 (0.37-9.27)
Extraintestinal manifestations
 No 326 1 1 1
 Yes 109 3.89 (2.47-6.14) 3.08 (1.87-5.08) 3.15 (1.92-5.18)
Immunosuppressant
 No 381 1
 Yes 54 1.19 (0.67-2.12)
Biologics
 No 262 1
 Yes 173 1.42 (0.96-2.10)
Surgery
 No 320 1
 Yes 115 1.36 (0.88-2.10)